Drug Trial Radar · NCT01979510
Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)
Last checked: Nov 20, 2026Latest source record: Apr 27, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Nov 2013
Primary completion
May 2014
Study completion May 2014
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 8, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of MK-0663B (etoricoxib/tizanidine) among participants with moderate-to-severe acute low back pain.
Conditions
- Low Back Pain
Interventions
MK-0663BDrug
MK-0663B once daily for 8 days.
DOLOCAM PLUS®Drug
DOLOCAM PLUS® once daily for 8 days.
Acetaminophen 500 mgDrug
Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing an Adverse Event (AE)Time frame: Up to Day 23
- Number of Participants Discontinuing Study Treatment Due to an AETime frame: Up to Day 8
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.